ClinicaliQ Trial Snapshot
- A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder — Recruiting • Phase III • NCT07219966.
- Trial testing whether brenipatide reduces alcohol use better than placebo in people with moderate-to-severe alcohol use disorder over 56 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks. Conditions: Alcohol Use Disorder Interventions: LY3537031, Placebo Lead Sponsor: Eli Lilly and Company Planned Enrollment: 1100 participants